Health
Dexamethasone use could reduce immune checkpoint inhibitor efficacy in glioblastoma patients – News-Medical.Net
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral…
Reviewed by Emily Henderson, B.Sc.Nov 25 2020
Bottom Line: Among patients with glioblastoma receiving an immune checkpoint inhibitor, those who received the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival.
Journal in Which the Study was Published: Clinical Cancer Research, a journal of the American Association for Cancer Research
Author: David A. Reardon, MD, clinical director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute in…
-
General11 hours agoChina and Philippines trade blame over latest South China Sea clash
-
Noosa News20 hours agoConfusion over licensing and access to hunting grounds under WA’s strict gun laws
-
General11 hours agoOf saints and sinners | The Spectator Australia
-
Noosa News16 hours agoBrisbane rising on global rankings, but still behind southern capitals